Literature DB >> 19347233

Potential of small molecule protein tyrosine kinase inhibitors as immuno-modulators and inhibitors of the development of type 1 diabetes.

Peter J Little1, Neale Cohen, Grant Morahan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19347233      PMCID： PMC5823116          DOI： 10.1100/tsw.2009.28

Source DB:  PubMed          Journal:  ScientificWorldJournal        ISSN： 1537-744X


× No keyword cloud information.
  4 in total

1.  Imatinib mesilate-induced phosphatidylinositol 3-kinase signalling and improved survival in insulin-producing cells: role of Src homology 2-containing inositol 5'-phosphatase interaction with c-Abl.

Authors:  D Mokhtari; A Al-Amin; K Turpaev; T Li; O Idevall-Hagren; J Li; A Wuttke; R G Fred; P Ravassard; R Scharfmann; A Tengholm; N Welsh
Journal:  Diabetologia       Date:  2013-03-05       Impact factor: 10.122

2.  Effects of Imatinib Mesylate (Gleevec) on human islet NF-kappaB activation and chemokine production in vitro.

Authors:  Dariush Mokhtari; Tingting Li; Tao Lu; Nils Welsh
Journal:  PLoS One       Date:  2011-09-14       Impact factor: 3.240

3.  Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia.

Authors:  Brittany M Duggan; Kevin P Foley; Brandyn D Henriksbo; Joseph F Cavallari; Akhilesh K Tamrakar; Jonathan D Schertzer
Journal:  Sci Rep       Date:  2017-05-08       Impact factor: 4.379

4.  Imatinib inhibits vascular smooth muscle proteoglycan synthesis and reduces LDL binding in vitro and aortic lipid deposition in vivo.

Authors:  Mandy L Ballinger; Narin Osman; Kazuhiko Hashimura; Judy B de Haan; Karin Jandeleit-Dahm; Terri Allen; Lisa R Tannock; John C Rutledge; Peter J Little
Journal:  J Cell Mol Med       Date:  2009-09-14       Impact factor: 5.310
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.